Drug Profile
Anti-CD16 monoclonal antibody - Sanofi/MacroGenics
Alternative Names: anti-CD16; CD16 Mab; GMA-161Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation; MacroGenics
- Class Monoclonal antibodies
- Mechanism of Action IgG receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Idiopathic thrombocytopenic purpura; Immunological disorders
Most Recent Events
- 29 Oct 2003 Preclinical trials in Immunological disorders in USA (unspecified route)